BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?

Last week, Bristol Myers (BMY) obtained FDA approval for a label expansion of its blockbuster immuno oncology drug Opdivo (nivolumab).The FDA approved Opdivo as a perioperative treatment regimen for adults with non-small cell lung cancer (NSCLC).FDA Nod for Perioperative Treatment Using OpdivoThe FDA approved Opdivo for the treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearr ...